Match score not available

Medical Science Liaison, Lead

Remote:

Full Remote

Experience:

Senior (5-10 years)

Work from:

Japan

Offer summary

Qualifications:

MD or PhD in medical/natural science preferred, Experience as MSL in life sciences, Strong basic science and clinical knowledge, Outstanding interpersonal and communication skills.

Key responsabilities:

Lead and develop a team of MSLs
Implement MSL strategy and collaboration with Clinical Development

Alnylam Pharmaceuticals Biotech: Biology + Technology Large https://www.alnylam.com/

1001 - 5000 Employees

See more Alnylam Pharmaceuticals offers

Job description

HEAD MSL JAPAN, TTR

Overview

The HEAD MSL, TTR Japan is a medical-scientific expert that strategically supports the medical-scientific objectives of Alnylam’s TTR programs.

He/she Will Report To The Medical Director, TTR Japan And Will Be Leading The MSL Team Of The Country And Will Ensure The Implementation Of The MSLs Activity Plan, Which Include

Evidence generation programs
Evidence dissemination and HCP education programs related to the science and clinical application of Alnylam’s RNAi platform
Key opinion leader engagement programs
Operational excellence.

The HEAD MSL, TTR is expected to build effective cross-functional relationships with colleagues in Medical Affairs, Clinical Research, R&D, Patient Advocacy and Commercial, and other while maintaining full compliance with all relevant company, industry, legal, and regulatory requirements.

Key Responsibilities

Lead, develop and coach a team of MSLs in the most efficient, effective and productive manner to reach set goals.
Develop and implement the MSL strategy and plan, including the support of launch readiness and post-launch medical as well as cross-functional programs and activities
Ensure MSL collaboration with the Clinical Development team to ensure timely and accurate implementation of research activities such a investigator initiated studies, collaborative studies and other clinical trials
Identify key opinion leaders who are experts in ATTR polyneuropathy and cardiomyopathy and collaborate with them and their organizations/institutions in the context of medical-scientific programs
Serve as a medical-scientific liaison for HCPs/the medical community and medical professional organizations and patient advocacy groups
Provide medical-scientific input concerning the program of medical-scientific advisory board meetings and ensure optimal planning and accurate execution of advisory board meetings
Collaborate with speakers to review (if required) their presentations in line with Alnylam’s SOPs and provide most accurate, objective and unbiased medical-scientific information if and when requested
Provide educational medical-scientific meetings support at scientific congresses

Qualifications

MD (Medical Doctor) and/or PhD and/or equivalent academically qualified professional. Degree in medical/natural science (PhD, MD) is preferred
Profound experience as MSL in the life science industry (pharmaceutical and biotechnology companies) in the therapeutic areas of cardiology (preferred) neurology and rare diseases
Highest degrees of work ethics
Proven self, team and strategic leadership skills
Ability to work in a matrix organization
Proven solid basic science and/or clinical knowledge and expertize to enable peer-to-peer level conversations with HCPs
Ability to cut through scientific complexity and synthesize complex content into clear and simple messages
Experience in clinical research (including investigator-sponsored trials, collaborative studies and phase IV studies)
Proven xperience in designing and implementing HCP education programs and KOL engagement programs
Ability to work collaboratively and cross-functionally
Excellent decision-making skills and ability to fully assume responsibility and accountability
Scientific publication experience is a plus
Dedicated, energetic and passionate about making a meaningful difference for patients and their caregivers
Outstanding interpersonal skills, including building strong working relationships, and managing and resolving conflict
Excellent communication skills, including presentation skills
An unwavering commitment to upholding the highest ethical, legal, regulatory and scientific standards
Fluent in Japanese and English, both written and verbal
Willing to travel 60% of the time

About Alnylam

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2022, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2023 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.